Phase II study of bendamustine, rituximab and cytarabine for patients with relapsed or refractory follicular lymphoma or mantle cell lymphoma
- Conditions
- relapsed or refractory follicular lymphoma or mantle cell lymphoma
- Registration Number
- JPRN-UMIN000009797
- Lead Sponsor
- Gifu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 13
Not provided
1) Patients are pregnant or lactating women. Patients (<1 year after menopause without surgical infertility) can not or will not use birth control during the treatment. 2) Patients have active other malignant diseases including simultaneous cancer and disease free state within 5 years after treatment for other cancer except curable intramural cancer by local treatment. 3) Patients have mental disease or disorder with difficulty in participating in the clinical trial. 4) HIV antibody positive, HBs antigen positive, HCV antibody positive 5) Patients have much tumor cell in peripheral blood (>=25,000/mm3). 6) Patients received allogeneic hematopoietic stem cell transplant. 7) Patients have interstitial lung disease or fibroid lung. 8) Patients have CNS invasion. 9) Patients are inappropriate for rituximab treatment. 10) Patients have severe allergic symptoms. 11) Inadequate for clinical trial entry by the attending physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method complete response rate
- Secondary Outcome Measures
Name Time Method overall response rate event free survival progression free survival safty peripheral blood stem cell harvest (transplant case)